Archive · 23 Sep 2025
Marksans Pharma's UK Arm Wins Approval for Blood Pressure Drug
Marksans Pharma's UK arm, Relonchem, has been given the green light to sell a drug called moxonidine in the UK.
This medicine is used to help people with high blood pressure.
This is good news because it means more people can get the medicine.
Relonchem also got approval for another drug, oxybutynin hydrochloride, earlier in June.
Although the company's profits decreased in the last three months, its sales actually went up.
The company's boss says the drop in profit was temporary.
Overall, the company is trying to grow, especially in places like the UK and the US.
Relonchem Limited received marketing authorization for moxonidine tablets in the UK.
Moxonidine is used to treat high blood pressure.
The company's US arm, Time-Cap Laboratories, got a positive inspection report.
Consolidated net profit fell by 34.3% year-on-year.
Revenue increased by 5% to ₹620 crore.
- Who
- Marksans Pharma and its UK subsidiary, Relonchem Limited
- What
- Received marketing authorization for moxonidine tablets for high blood pressure in the UK.
- When
- Authorization received recently; financial data from Q1 FY26
- Where
- United Kingdom, specifically the UK Medicines and Healthcare Products Regulatory Agency (MHRA).
- Why
- To expand their portfolio and treat high blood pressure.
- Company
- Marksans Pharma Ltd
- Subsidiary
- Relonchem Limited (UK)
- Drug Approved
- Moxonidine (for high blood pressure)
- Drug Strengths
- 200 and 400 microgram
- Previous Approval
- Oxybutynin hydrochloride oral solution (June)
- Financials
- Consolidated net profit down 34.3% YoY, Revenue up 5% YoY
- Share Price
- ₹171.72 (down 1.45%)